- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03297905
Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury
Determinants of the Optimal Dose and Sequence of Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Objectives and Rationale. Pain due to neuromusculoskeletal injuries is a leading cause of disability among active duty military Service members. The injury rate is significant with 628 neuromusculoskeletal injuries per 1000 person-years among active duty military Service members. Neuromusculoskeletal injuries include amputations following battlefield trauma, repetitive motion injuries related to equipment use or weight-bearing postures, and even injuries or strains incurred during off-duty pursuits. Regardless of cause, the effects on both individual Service members and military readiness are significant: Only 13% of Service members being treated primarily for pain ever return to the field.
The Department of Defense (DoD) has recently expanded its capacity to provide both functional restoration (FR) and complementary and integrative medicine (CIM) therapies for neuromusculoskeletal injury, pain, and disability. The proposed research aims to determine the most effective treatment combination, sequence, and duration of standard rehabilitative care (SRC), such as physical and occupational therapy in combination with cognitive behavioral therapy and CIM therapies, such as acupuncture and chiropractic, for Service members preparing to enroll in an intensive FR program that is currently the DoD-recommended treatment. In addition, this study aims to identify ways to predict in advance which patients will respond best to which therapeutic regimens.
Potential Impact. This research has the potential to determine which patients are most likely to benefit from the non-medication pain therapies currently available in all Army Interdisciplinary Pain Management Centers (IPMC) and how these therapies can most effectively be combined to achieve the greatest improvements in pain impact, quality of life and ability to return to duty following injury.
Patients Who Will Benefit. This study will involve active duty Service members referred to an Army IPMC. The results will be shared with other Military Health System (MHS) and Veterans Health Administration (VHA) pain management centers so that active duty Service members and veterans across United States may benefit from a treatment approach that is tailored to their individual characteristics. It is anticipated that the knowledge gained through this research will be applicable to family members of Service members and veterans and will ultimately lead to expansion of TRICARE benefits to include CIM therapies.
Potential Clinical Applications, Benefits, and Risks. This research will assist providers in determining when to refer their patients with neuromusculoskeletal pain for SRC and/or CIM therapies prior to FR. It will assist IPMCs in developing treatment plans tailored to the needs of each patient. Service members and veterans will benefit by being referred for these approaches when appropriate during the course of disabling chronic pain conditions. Ultimately, it is hoped that decision tools can be imbedded in the electronic medical record to guide health care providers to consider referral for these therapies in patients who may benefit. This study will advance our ability to effectively tailor therapies for rehabilitation from neuromusculoskeletal pain for different patients to yield the greatest benefit in physical function and quality of life. The risks of these interventions are minimal; Service members may experience general muscle soreness for the first week or so of increased physical activity, but this typically resolves.
Projected Timeline. This research will determine the optimal combination, sequence, and duration of therapies. It is expected that some active duty Service members could see improvements in function and quality of life within three weeks, but others may require up to six weeks to experience meaningful improvement.
Benefit to Military Personnel. This research will benefit Service members experiencing pain due to neuromusculoskeletal injury. It will identify ways to direct them to the therapies most likely to yield meaningful improvements in function and quality of life, and thus facilitate their return to duty. The recommendations from this study will be shared with pain management centers throughout the DoD, VHA; and, we hope, eventually to TRICARE members.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Washington
-
Tacoma, Washington, Estados Unidos, 98431
- Madigan Army Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Active duty service members
- Neuromusculoskeletal or neuropathic pain ≥ 3-months duration
- Pain of sufficient severity to bring about dysfunction in daily social, vocational, and/or interpersonal activities
Exclusion Criteria:
- Major surgeries within past 6 months or planned within next 6 months
- Unstable psychological disorders
- Active substance use disorder
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Complementary and Integrative Therapies
Chiropractic, Acupuncture, Yoga, Biofeedback (if indicated), and Foam roller instruction
|
Intervention time period is 3 - 6 weeks.
|
Comparador activo: Standard Rehabilitative Care
Cognitive Behavioral Therapy (CBT) 60-minute orientation, CBT psychoeducation group, and Physical therapy/occupational therapy
|
Intervention time period is 3 - 6 weeks.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change from Baseline Pain Intensity
Periodo de tiempo: 3 months
|
Pain Intensity 10-pt Numeric Rating Scale
|
3 months
|
Change from Baseline Pain Impact
Periodo de tiempo: 3 months
|
Aggregate score calculated from Defense and Veterans Pain Rating Scale (DVPRS)
|
3 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Depression
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Patient Reported Outcome Measurement Information System
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Anxiety
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Patient Reported Outcome Measurement Information System
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Emotional Distress - Anger
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Patient Reported Outcome Measurement Information System
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Sleep Disturbance
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Patient Reported Outcome Measurement Information System
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Fatigue
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Patient Reported Outcome Measurement Information System
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
PTSD
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Primary Care PTSD Screen
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Patient Activation Measure
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
A 22-item survey that addresses four stages of patient activation: (1) believing the patient role is important, (2) having the confidence and knowledge necessary to take action, (3) actually taking action to maintain and improve one's health, and (4) staying the course even under stress.
Patients are asked to agree or not to agree with each of the 22 items.
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Drug Use
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Drug Use Questionnaire
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Pain Catastrophizing
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Pain Catastrophizing Scale
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Kinesiophobia
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Tampa Scale for Kinesiophobia
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Pain Self-Efficacy
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Pain Self Efficacy Questionnaire
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Chronic Pain Acceptance
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Chronic Pain Acceptance Questionnaire
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Functional Capacity
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Roland-Morris Disability Questionnaire and Canadian Occupational Performance Measure
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Opioid Utilization
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Opioid Utilization Screener
|
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
|
Cortisol
Periodo de tiempo: baseline, 6 weeks
|
Salivary Cortisol
|
baseline, 6 weeks
|
Oxidative Stress
Periodo de tiempo: baseline, 6 weeks
|
Urine Sample
|
baseline, 6 weeks
|
Genomic DNA
Periodo de tiempo: baseline
|
Buccal Sample
|
baseline
|
Army Physical Fitness Test (APFT)
Periodo de tiempo: baseline, 6 weeks, 3 months, 6 months
|
Passing scores of 60 on all 3 components (push-ups, sit-ups, 2-mile run) of the APFT will be operationalized as "force-readiness".
|
baseline, 6 weeks, 3 months, 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ardith Z Doorenbos, RN, PhD, University of Washington
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STUDY00004220
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .